FDA
-
-
-
-
-
-
-
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
-
-
-
-
-
-
-
Truist Securities Reiterates Buy Rating on MBX Biosciences Inc (MBX)
-
-
-
-
-
-
-
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
Microbix Partners with SEKISUI Diagnostics to Support COVID/Flu Tests
-
-
-
-
-
-
-
MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension
-
-
-
-
-
-
-
Microbix Schedules Release of Results for Q3 Fiscal 2025 Results Release and Webinar Discussion on Morning of August 14, 2025
-
-
-
-
-
-
-
MBX Biosciences (MBX) Announces IND Submission of MBX 4291
-
325,893 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

